Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers

Sanna Ali

Peg Esper

prostate cancer, brachytherapy, radiation therapy, cancer risk, localized prostate cancer
CJON 2021, 25(3), 321-328. DOI: 10.1188/21.CJON.321-328

Background: Brachytherapy is a well-established and effective primary treatment modality for low- and favorable intermediate–risk prostate cancers. Although the benefits of brachytherapy in unfavorable intermediate– and high-risk prostate cancers have not been as clear, research suggests that brachytherapy boost may improve biochemical progression-free survival in these patients.

Objectives: This article aims to discuss evidence for the revival of brachytherapy use in unfavorable intermediate– and high-risk prostate cancers and specific nursing implications in the management of these patients.

Methods: The literature on brachytherapy and its use to treat localized prostate cancers was reviewed.

Findings: Nurses should be knowledgeable about the indications for brachytherapy, patient eligibility, anticipated side effects, and symptom management.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.